GVK Bio to move into US with Aragen Purchase; Asia’s leading small-molecule CRO GVK BIO will acquire the capital stock of US-based CRO Aragen Bioscience.
In: Outsourcing-Pharma.com (UK), 2014-01-30, S. 1
Zeitungsartikel
Zugriff:
The deal for Aragen Bioscience, a privately held, pre-clinical CRO specializing in high-value biologics services, deal enables GVK BIO to expand its service offering to a broader base of organizations and gives GVK BIO expertise in biologics services and a significant US presence. "As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO's ability to offer high quality R&D services to the industry from a seamless integrated platform," said Mr...
Titel: |
GVK Bio to move into US with Aragen Purchase; Asia’s leading small-molecule CRO GVK BIO will acquire the capital stock of US-based CRO Aragen Bioscience.
|
---|---|
Zeitschrift: | Outsourcing-Pharma.com (UK), 2014-01-30, S. 1 |
Veröffentlichung: | 2014 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|